Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2021
- The Future of Generics
Advertise

Search

Search

Close

Trending

Data backs AZ’s Wilson disease drug, but with a question mark

Fujifilm acquires AI tech to improve fertility treatment

Sarepta shares yo-yo as FDA places hold on Duchenne trial

New countries stockpile antiviral TPOXX as monkeypox outbreak continues

Biogen and Happify partner on digital support for MS patients

EHA 2022

Daiichi-Sankyo-sign

News/ News/ News/ Oncology/ R&D

EHA: Survival data sets Daiichi Sankyo’s quizartinib back on track

Phil Taylor acute myeloid leukaemia, Astellas, Daiichi Sankyo, EHA 2022, FLT3 inhibitor, Novartis, quizartinib, Rydapt, Xospata 0 Comment

Three years after Daiichi Sankyo’s FLR3 inhibitor quizartinib was rejected by the FDA, the drugmaker has reported the

X

EHA: Survival data sets Daiichi Sankyo’s quizartinib back on track

https://pharmaphorum.com/news/eha-survival-data-sets-daiichi-sankyos-quizartinib-back-on-track/

sickle cell

News/ News/ R&D

EHA: Vertex, CRISPR build case for gene-editing drug

Phil Taylor beta thalassaemia, CRISPR Therapeutics, CRISPR/Cas9, EHA 2022, gene editing, sickle cell disease, Vertex Pharma 0 Comment

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has continued to show impressive results in clinical

X

EHA: Vertex, CRISPR build case for gene-editing drug

https://pharmaphorum.com/news/eha-vertex-crispr-build-case-for-gene-editing-drug/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Patient Engagement Event - a real world snapshot, beyond the talk

Patient Engagement Event - a real world snapshot, beyond the talk

Most popular

Most Viewed

Novartis faces threat of early generic of MS drug Gilenya in US
Novartis bags FDA okay for BRAF-positive tumour combination
Pfizer is first big pharma to tap Truveta's real-world data platform
AbbVie files Qulipta for chronic migraine prevention
Moderna facility in UK confirmed, part of 10-year deal with gov't

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise
pharmaphorum connect

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com